Report scope. This 2026 Drug Asset Due Diligence Report evaluates Zaltenibart as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Zaltenibart is a Monoclonal antibody associated with MASP-3 and a global highest development stage of Phase 2. The lead disclosed indication is C3 glomerulopathy. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Zaltenibart
- Target: MASP-3
- Lead indication: C3 glomerulopathy
- Highest phase: Phase 2
- Matched trials: 6
- Matched result records: 6
- Matched asset deals: 2
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Zaltenibart, the MCP profile identifies MASP-3 as the primary target context and C3 glomerulopathy as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06298955 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| ISRCTN16253842 | Phase 1 | No longer recruiting | Not disclosed | Not disclosed |
| NCT06209736 | Phase 2 | Recruiting | Not disclosed | Not disclosed |
| NCT05972967 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT05889299 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NL-OMON49225 | Not Applicable | Withdrawn | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
3. Clinical readouts: what is known
DOSE DETERMINATION FOR A RARE INDICATION: PHASE 3 DOSE OF ZALTENIBART, AN INVESTIGATIONAL MASP-3 INHIBITOR, FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Study: PB2794 (EHA2025). Phase: Phase 3. Enrollment: Not disclosed. Published: 2025-05-14.
ARC decrease = -101 ×10^9/L | ARC decrease = -116 ×10^9/L
ZALTENIBART, AN ALTERNATIVE PATHWAY OF COMPLEMENT MASP-3 INHIBITOR, IMPROVED HEMATOLOGIC PARAMETERS IN PNH PATIENTS WITH PERSISTENT ANEMIA ON RAVULIZUMAB: ADJUNCTIVE AND MONOTHERAPY TREATMENT PHASES
Study: NCT05972967 (PF659, EHA2025). Phase: Phase 2. Enrollment: 13. Published: 2025-05-14.
ARC = -115 ×10^9/L | ARC = -103 ×10^9/L
4072Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Study: ASH2024. Phase: Not Applicable. Enrollment: Not disclosed. Published: 2024-12-09.
ARC = 112 x10^9/L
OMS906, A NOVEL ALTERNATIVE PATHWAY MASP-3 INHIBITOR, IMPROVED HEMATOLOGIC PARAMETERS IN PNH PATIENTS WITH SUBOPTIMAL RESPONSE TO RAVULIZUMAB TREATMENT: PHASE 2 DOSE-FINDING STUDY INTERIM RESULTS
Study: NCT05972967 (EHA2024). Phase: Phase 2. Enrollment: 13. Published: 2024-05-14.
TRAE = 38.5 %
573 OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients
Study: NCT05889299 (ASH2023). Phase: Phase 1. Enrollment: 11. Published: 2023-12-10.
Hemoglobin level = 7.0 g/dL
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects
Study: ASH 12022 | ASH 22022. Phase: Phase 1. Enrollment: 72. Published: 2022-11-15.
ISR = 3.3 % | ISR = 70.8 %
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Zaltenibart against approved therapies and clinical competitors in C3 glomerulopathy, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2025-10-15 | Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) | Completed | Asset Acquisition, License | Disclosed |
| 2018-12-11 | Omeros Announces Research Collaboration With University Of Cambridge | Active | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Zaltenibart diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
